Life Sciences & Medicine Active Updated Oct 7, 2026
The many-fronted fight against Alzheimer's
Where it stands as of Oct 2, 2026
The work now spans seven fronts: how tau spreads, drugs that retune the brain's immune cells, blood tests that catch the disease early, genetic risk scores built for different ancestries, the folding of the genome inside brain cells, a placenta-derived nasal spray in mice, and now damage to the brain's blood vessels in APOE4 carriers. Mount Sinai researchers found that blocking TGF-β signaling restored pericyte coverage and cut fibrosis and amyloid in aged APOE4 mice. Nobody has tried blocking TGF-β in a person, so
Researchers are attacking Alzheimer's from several directions at once: the biology of how it spreads, drugs that reprogram the brain's immune cells, and blood tests that could catch it years early.
Oct 7, 2026 Latest
A neurotoxicologist and colleagues reported in npj Dementia that the aging dog brain changes in ways similar to a human brain with dementia. Canine cognitive dysfunction affects more than a quarter of dogs over age 12, and the team compared brains of affected dogs with those of people with Alzheimer's, using samples donated by owners.
Oct 6, 2026
Birmingham researchers reported that blocking the P2X7 receptor stopped inflammatory cytokine release in living human brain slices taken during neurosurgery. Drugs that block P2X7 have already been through clinical testing, but the work is in tissue, not patients.
Oct 2, 2026
Two Mount Sinai studies, in Cell and Cell Stem Cell, reported that in carriers of the APOE4 gene, pericytes around small brain blood vessels turned into scar-laying myofibroblast-like cells, causing vessel fibrosis and more amyloid buildup. Blocking TGF-β signaling restored pericyte coverage and reduced fibrosis and amyloid, including in aged APOE4 mice, and the second paper described a stem-cell-derived human brain tissue platform for faster drug testing.
Oct 1, 2026
Nature and ScienceAlert reported that harmful tau spreads like a self-propagating prion protein, with ScienceAlert describing the Alzheimer's protein behaving as a prion does in mouse brains.
Sep 30, 2026
David Holtzman's group at Washington University in St. Louis reported in Neuron that an antibody blocking the T cell receptor CXCR3 cut brain-infiltrating T cells by roughly half in mice with Alzheimer's-like tau pathology. Treated mice kept about 40% more tissue in their memory centers and did significantly better on memory tests, while their tau tangles stayed at the same level.
Sep 26, 2026
PsyPost reported a study found midlife belly fat was linked to elevated Alzheimer's biomarkers decades later.
Sep 25, 2026
A study found brain structure changes appeared up to seven years before Alzheimer's-related plaques could be detected, PsyPost reported.
Sep 24, 2026
A study found Alzheimer's-related proteins could predict early brain shrinkage before dementia symptoms appeared, PsyPost reported.
Sep 23, 2026
The World Alzheimer Report 2026 described the disease shifting from something doctors could only watch to something they might interrupt, citing drugs including donanemab and lecanemab and noting more than a third of pipeline candidates were originally developed for other conditions.
Sep 16, 2026
A mouse study found a nasal spray derived from human placenta protected against Alzheimer's-related cognitive decline, ScienceAlert reported.
Sep 14, 2026
A Carnegie Mellon, University of Pittsburgh and University of Washington team used a technique called GAGE-seq on postmortem prefrontal cortex tissue to show that the genome's three-dimensional folding pattern is disrupted in several types of brain cells affected by Alzheimer's, identifying genome architecture as a regulatory layer distinct from amyloid and tau.
Sep 6, 2026
UC San Francisco researchers led by Meri Okorie and Shea J. Andrews built a multi-ancestry Alzheimer's polygenic risk score using genetic data from hundreds of thousands of people of European, African, Admixed American, East Asian and Caribbean Hispanic descent, and found it predicted Alzheimer's diagnosis more accurately across every group than a Europe-only score while also tracking the underlying brain damage the disease causes.
Sep 1, 2026
A University of South Carolina team built a molecular cage that delivers an antibody into astrocytes to release a protein brake holding their identity in place, converting astrocytes into firing neurons in lab dishes and human brain organoids, and in an Alzheimer's mouse model the treatment grew new neurons in the hippocampus and brought treated mice to healthy-mouse performance on memory maze tests.
Aug 30, 2026
A Mount Sinai-led team mapped 830,000 brain immune cells from 1,607 donors and identified a microglia subtype that expands to actively fight Alzheimer's disease as it progresses, giving future treatments a defense system to strengthen instead of only plaques to attack.
Aug 24, 2026
The FDA approved C2N Diagnostics' PrecivityAD2 blood test, the first cleared for symptomatic Alzheimer's patients as young as 40, which correctly identified 97.6 percent of positive amyloid and tau biomarkers in a validation study of 1,142 symptomatic adults and held up even in people with kidney disease or diabetes.
Aug 11, 2026
Nautilus reported that a 2024 study of nearly 9 million US death certificates found taxi and ambulance drivers, who rely on continuous real-time navigation rather than fixed routes, had the lowest Alzheimer's death rate of 443 occupations, about 1 in 100 versus 1 in 60 in the general population, echoing earlier findings that London cabbies who memorized the city's street layout developed measurably more gray matter in the hippocampus.
Aug 1, 2026
New Scientist reported that thousands of people in China have received a lymphatic drainage surgery for Alzheimer's that remains banned in most countries, after small safety trials in the US and Singapore found it safe for up to six months with some signs of cognitive improvement, and a randomized trial against a sham procedure is now underway to test whether it actually works.
Jul 27, 2026
A VIB, KU Leuven, UK Dementia Research Institute and Muna Therapeutics team, publishing in Nature Medicine, compared brain tissue from people with dementia, cognitively healthy older adults, and cognitively healthy centenarians and found some centenarian brains carried heavy amyloid and tau pathology without memory loss. Co-senior author Bart De Strooper's team traced the difference to microglia shifting into distinct protective states in the resistant brains.
Jul 25, 2026
Buck Institute researchers led by Lisa Ellerby engineered human stem cell-derived neurons differing only in APOE genotype and found APOE2 neurons accumulated less DNA damage, switched on DNA repair pathways more strongly, and resisted cellular senescence, with aged mice carrying the human APOE2 gene showing the same pattern in hippocampal tissue.
Jul 21, 2026
A University of Kentucky team led by Shannon Macauley and Nicholas Constantino found that in mice with amyloid plaques, sleep loss traces not to the plaques themselves but to microglia triggering broad brain inflammation while clearing them. Temporarily depleting the microglia restored more than two hours of deep, slow-wave sleep a day without clearing any plaques.
Jul 19, 2026
KCL-286, a drug already proven safe in human Phase 1 trials for a different condition, repaired DNA damage and cut inflammation in a mouse model of Alzheimer's, targeting the disease at a stage before amyloid plaques even form.
Jul 15, 2026
A study led by Kaley Hayes at the University of Massachusetts found older adults recently discharged from skilled nursing facilities who received the recombinant shingles vaccine Shingrix had a lower rate of new dementia diagnosis over four years, enough to estimate the shot could prevent roughly one in 17 cases. The effect builds on an older, discontinued shingles vaccine that showed the same signal, and on the idea that shingles itself inflames the brain and raises stroke risk.
Jul 11, 2026
A University of Kansas Medical Center study found Alzheimer's patients who took daily creatine for two months showed measurable increases in brain energy levels and cognitive test scores, testing the idea that refueling neurons running low on cellular energy helps alongside existing plaque-targeted treatments.
Jul 8, 2026
A Monash University team treated an Alzheimer's mouse model with a copper compound called Cu(ATSM) for 56 days and found P-glycoprotein pump abundance at the blood-brain barrier rose 24.1 percent, amyloid-beta in the brain dropped 42 percent, and spatial learning improved by nearly 44 percent. The approach targets the brain's own waste-clearance system rather than attacking toxic proteins directly. Cu(ATSM) has already been tested in human clinical trials for Parkinson's disease and ALS, giving it an unusual head start on safety evaluation.
Jul 7, 2026
Mass General Brigham researchers confirmed for the first time in humans that the BCG tuberculosis vaccine can cross the blood-brain barrier into cerebrospinal fluid. In healthy older adults without existing Alzheimer's pathology, BCG shifted amyloid-beta levels downward in cerebrospinal fluid while raising them in the bloodstream, suggesting the vaccine helped push the protein out of the central nervous system. The protective shift was absent in participants who already had established Alzheimer's biomarkers, indicating timing is critical.
Jul 2, 2026
Scientists identified a set of circulating RNA molecules in the blood that flagged Alzheimer's onset two to four years before symptoms appeared.
Jun 30, 2026
A University of Utah team showed Alzheimer's spreads tau using the brain's own transport system via the Arc protein, and that blocking Arc cut the spread by about 99 percent in mice.
Jun 20, 2026
Researchers reported a molecule that reprograms the brain's own immune cells, the microglia, to restore their protective function against Alzheimer's damage.
Jun 18, 2026
A study from Niigata University found that APP, the protein most often blamed for Alzheimer's, also acts as a cellular cleaner that protects neurons, complicating the simple plaque story.
The checkable promises in this story, dated the day they were made. A promise is marked kept, slipped or partly met only when a later report says so; past its own date with no report, it reads "no word", which is what silence honestly is.
Promising Alzheimer's drugs can slow progression when started early, but the infrastructure for population-scale screening does not yet exist.
Reporting in the Today Got Better brief
several promising Alzheimer's drugs have shown they can slow progression when started early, but the clinical infrastructure for population-scale screening does not exist yet
When this question gets a new answer, the page above changes the same morning. Each morning's letter brings the day's progress in science, medicine and beyond. Free, every day.
Free forever, no spam. One click to unsubscribe, and we never sell your email.